News


 IT | 2008-07-15
Maeglin Software lève 750 000 € auprès de CDC Innovation et Innovacom

Paris, le 15 juillet 2008 - Maeglin Software, start-up spécialisée dans le développement et la commercialisation de services innovants pour mobiles, vient de lever 750 000 € auprès des sociétés de capital investissement CDC Innovation, filiale du groupe Caisse des Dépôts, et Innovacom, filiale capital-risque du groupe France Telecom. Ces deux investisseurs ont rejoint le capital de Maeglin Software fin 2007 lors du rachat de la société Ipracom.
 
Cette première levée de fonds auprès d’investisseurs institutionnels fait suite à l’augmentation de capital auprès de business angels d’avril 2007. Maeglin Software, présente à Montpellier et Paris, bénéficie aussi depuis 2006 du soutien d’OSEO, de Languedoc Roussillon Incubation, et de la Région Languedoc-Roussillon.
 
Investissements marketing et commerciaux
 
Les fonds levés vont permettre à Maeglin Software d’accélérer le développement de Pleex, réseau social mobile dont un des services phare est la sauvegarde en ligne de contenu mobile. Jean-François Auriffeille, PDG de Maeglin Software, déclare : « CDC Innovation et Innovacom nous permettent d’augmenter de façon significative nos investissements marketing et commerciaux et notre développement international. Nous pouvons aussi continuer nos efforts de développement avec plusieurs lancements produits dans les mois qui viennent. » Franck Noiret, General Partner de CDC Innovation, ajoute : « Nous pensons qu’avec Pleex, Maeglin Software est sur un marché très porteur, à la croisée de la convergence Web-mobile, de la protection des données et des services communautaires. Il nous semblait donc important d’accompagner Maeglin Software et son équipe dans son développement. »
 
Enfin LA solution simple et gratuite pour sauvegarder le contenu d’un mobile sur le Web
 
Tous les ans en France, un million de téléphones sont perdus, volés ou cassés. Pleex répond à ce problème en protégeant le contenu du mobile. Pleex, disponible en français et en anglais pour plus de 300 modèles de téléphone, permet de sauvegarder sur www.pleex.com le répertoire (SIM et téléphone), les photos, les vidéos, les MP3 et les documents de son téléphone mobile. Cette sauvegarde se fait sans câble ni PC, par le réseau data opérateur. L’utilisateur peut aussi gérer ses contacts en ligne et les restaurer sur son téléphone.

 Maeglin Software est une start-up spécialisée dans le développement et la commercialisation de services pour mobiles. Cette Jeune Entreprise Innovante (JEI) implantée à Paris et à Montpellier a été fondée en 2006. MAEGLIN est financée par CDC Innovation, Innovacom, Cap Décisif et plusieurs business angels et bénéficie du soutien d’OSEO, de LRI (Languedoc Roussillon Incubation) et de la Région Languedoc-Roussillon. Maeglin est accompagnée par le CEEI de Montpellier. Pour en savoir plus www.maeglin.com

 CDC Innovation, créée en 1996, est une société internationale de venture capital avec son siège à Paris et une présence locale dans la Silicon Valley et en Suisse. Avec plus de 415 M€ de fonds sous gestion, elle investit dans des entreprises innovantes en phase de premiers développements ou en phase de croissance, dans deux secteurs: les technologies de l'information et les sciences de la vie. Son objectif est de créer de la valeur en apportant à des entrepreneurs de talent les ressources, l'expérience et le réseau nécessaires pour transformer des sociétés technologiques à haut potentiel en de véritables succès industriels.

 
 Innovacom créée en 1988 par France Telecom (www.innovacom.com) a participé au lancement de jeunes sociétés innovantes dans les domaines des télécommunications, des technologies de l'information et des média, telles que Alapage.com, Business Objects, Cobalt Networks, Envivio, Gemplus, Infovista, Intershop, Inventel, Kelkoo, Last Minute.com, Netcentrex, Soitec et Tumbleweed. Avec 600M€ sous gestion et des bureaux à Paris, San Francisco et Stockholm, Innovacom est un investisseur en capital-risque actif en Europe et en Amérique du Nord. Innovacom investit à la fois dans des sociétés au stade de la création et dans des sociétés ayant réussi leur démarrage avec une première base de clientèle et des revenus. Innovacom accompagne les différentes étapes de financement des sociétés de son portefeuille jusqu'à une cession industrielle ou boursière et soutient leurs efforts de «Business Development » auprès du Groupe France Telecom / Orange.



 IT | 2008-07-04
Anevia appoints Pierre Yves Le Berre as Marketing and Business Development Director

Anevia hires Netcentrex VP to lead Anevia’s business development

Paris, 4 July 2008

Anevia, a leading solution provider for video over IP with FLAMINGO DVB to IP gateways and the TOUCAN VOD/nPVR servers is pleased to announce today the appointment of Pierre-Yves Le Berre as Marketing and Business Development Director.

Back in 2002, he succeeded for five years as Vice-President of Netcentrex in charge of strategy and business development, which was acquired by Comverse in 2006. Prior to that, he held senior positions at Nortel Networks and Matra Communication in marketing and business development and has a track record of managing successfully high-tech activities in early-stage and fast growing phase. He has a MBA from ESC Grenoble.

Based in Paris, he takes on the challenge of anticipating market trends and crafting the adequate strategies. His extensive experience from over 20 years in new market development and business model definition in telecommunications worldwide is a key asset to accelerate Anevia’s expansion into high potential markets such as fixed-mobile applications, as well as to strengthen its position as a leader supplier in video service infrastructure.

About Anevia

Anevia is a solution provider, specialized in the video component of Triple Play – IPTV, VoD, Catch-Up TV and network PVR. Anevia’s added value lies in its innovative software solution, which combines broadband and television. Anevia's VoD/nPVR TOUCAN servers and DVB to IP FLAMINGO gateways are compact, cheap and easy to deploy.Anevia services more than 300 clients across 50 different countries.



 IT | 2008-05-30
Maeglin Software sélectionné au « French Tech Tour » San Francisco et Silicon Valley

Maeglin Software, startup spécialisée dans le développement et la commercialisation de services pour mobiles,implantée à Montpellier et à Paris a été selectionnée comme « l’une des 11 stars françaises » pour participer du 19 au 23 mai au « French Tech Tour » de San Francisco et de la Silicon Valley. Cet événement est organisé par la Mission Economique de San Francisco, de l’Ambassade de France aux Etats-Unis et UbiFrance. A cette occasion, Google, Microsoft, AT&T (premier opérateur télécom aux Etats-Unis), et Symantec (leader mondial des logiciels anti-virus) ont souhaité rencontrer Jean-François Auriffeille, PDG de Maeglin Software.
 
Lors de tête-à-tête avec les Vice-présidents, Business Development de ces sociétés, Jean-François Auriffeille a eu l’occasion de leur présenter Pleex, www.pleex.com, le service de sauvegarde de contenu mobile et de communauté mobile de proximité de Maeglin Software. Ils ont ensuite pu échanger sur les opportunités de partenariats entre Maeglin Software et leurs sociétés respectives.
 
Outre de nombreuses interviews de Jean-François Auriffeille par BFM, C Net, et Uberpulse, cet événement a surtout permis de présenter PLEEX à plus de deux cents entrepreneurs, capitaux risqueurs et Vice-présidents Business Development de la Silicon Valley.
 



 IT | 2008-05-28
CDT, Sumitomo Chemical and Novaled will collaborate to evaluate Novaled PIN OLED structures in Polymer OLED devices.

05/28/2008
 
CDT and Sumitomo Chemicals, leaders in polymer organic light emitting diode (P-OLED) devices, and Novaled, the leader in high efficiency p-i-n OLED structures and dopant materials, have agreed to collaborate under a joint development agreement to investigate the feasibility and benefits of new materials and Novaled PIN OLED structures in P-OLED devices.
 
CDT, Sumitomo and Novaled plan to co-develop hybrid OLED devices combining both new polymer emitting layers and doped electron transport layers. It is expected that these hybrid devices will offer further improvements in power efficiency without additional manufacturing complexity. The parties have reached an agreement on how IP generated during the JDA will be handled. Further, Novaled will grant a license to CDT enabling CDT to add necessary Novaled device IP to its existing and future licenses. Each company will remain responsible to market its own materials resulting from this co-development.
 
"CDT continues to focus its effort on supporting the P-OLED supply chain and is pleased to be involved in yet another joint development project which has the potential of bringing new materials and improved device performance to our licensees", says David Fyfe, CEO of CDT.
 
"We are excited about the prospect of including new materials and device structures arising from a successful JDA between CDT and Novaled in our product plans. Having the support from CDT and Novaled, leading companies in their fields, increases the potential range of new products we can offer to the market", says Kazuhiko Miyata, General Manager of Sumitomo New Business Development office.
 
"Novaled, with its Novaled PIN OLED technology, is a leader in high efficiency OLED devices and a recognized supplier of specialised dopants and organic transport materials", says Gildas Sorin, CEO of Novaled. "We are pleased to contribute to the development of P-OLED devices and look forward to a successful collaboration with both CDT and Sumitomo Chemical. This co-development agreement is consistent with our strategy to promote our dopants in all organic electronic fields."
 
About P-OLEDs
 
P-OLEDs have a number of intrinsic advantages over other display technologies. For example,
 
P-OLED , as part of the family of OLEDs, is an emissive technology: P-OLED devices emit light as
a function of their electrical operation.
 
P-OLED displays consists of polymer materials deposited on a substrate of glass or plastic, and
do not require additional elements such as backlights or filters.
 
P-OLED technology is very energy efficient and lends itself to the creation of ultra-thin lighting
displays that will operate at lower voltages.
 
The resulting benefits include brighter, clearer displays with viewing angles approaching 180 degrees, simpler construction offering the potential for cheaper, more robust display modules, and ultra-fast response times allowing full colour video pictures even at low temperature.
 
About CDT
 
Cambridge Display Technology (CDT), headquartered at Cambourne near Cambridge in the UK, is a pioneer in the development of polymer organic light emitting diodes (P-OLEDs) and their use in a wide range of electronic display products used for information management, communications and entertainment. P-OLEDs are part of the family of OLEDs, which are thin, lightweight and power efficient devices that emit light when an electric current flows. P-OLEDs offer an enhanced visual experience and superior performance characteristics compared with other flat panel display technologies such as liquid crystal displays, and have the key advantage that they can be applied in solution using printing processes. CDT was acquired by Sumitomo Chemical in September 2007. Together, CDT and Sumitomo lead the research and commercialization of light emitting polymer technology used in displays and lighting applications. More information on CDT can be found at: www.cdtltd.co.uk
 
About Sumitomo Chemical
 
Sumitomo Chemical Co. Limited is one of Japan's leading chemical companies with sales of 1,897Billion JPY(consolidated) ended March 31, 2008, offering a diverse range of products in the fields of basic chemicals, petrochemicals, fine chemicals, IT-related chemicals, agricultural chemicals, and pharmaceuticals. Sumitomo Chemical has positioned display materials as one of its core business areas and, while it continues to expand its liquid crystal display materials business, it is also concentrating its efforts on the development of next-generation display materials with a particular focus on P-OLEDs.
Sumitomo Chemical's development of P-OLEDs began in 1989. In 2001, Sumitomo Chemical and CDT Ltd. of Cambridge, England, entered into a technical assistance agreement, including technology licensing for light-emitting materials, and in May 2002, Sumitomo Chemical made an equity investment in CDT Ltd. to build a closer working relationship for the commercialization of P-OLEDs. Subsequently Sumitomo and CDT formed a joint venture - Sumation - to develop and commercialise the P-OLED materials themselves.
While expanding business worldwide and aggressively pursuing cutting-edge R&D, Sumitomo Chemical continually strives to contribute to the sustainable development of society through its Responsible Care activities.
More information on Sumitomo Chemical can be found at: http://www.sumitomo-chem.co.jp/english/index.html
 
About Novaled
 
Novaled AG is a world leading company in the OLED (organic light-emitting diode) field specialized in high efficiency long lifetime OLED structures and an expert in synthetic and analytical chemistry. The company offers complete solutions to the organic electronic markets, commercializing its Novaled PIN OLEDTM technology along with its proprietary OLED materials.
Novaled has developed long term partnerships with major OLED players worldwide. Based on more than 380 patents granted or pending, Novaled has a strong IP position in OLED technology.
Main investors are Crédit Agricole Private Equity, TechnoStart, TechFund Capital Europe and CDC Innovation. For more details please visit www.novaled.com
 
 
 
 
 
 
 
 
 
 



 IT | 2008-05-21
PRO TECHnology and Anevia deploy a state-of-the-art IPTV solution for Abu Dhabi Media Corporation

UAE’s largest media group to utilise cost effective and user-friendly FLAMINGO DVB to IPTV Gateway solution

May 21, 2008

PRO TECHnology, a leading provider of communication, security and storage solutions, and Anevia, a leading vendor of next generation Video on Demand (VOD) and Internet Protocol Television (IPTV) head-end servers, have partnered to deploy a state-of-the-art IPTV solution within Abu Dhabi Media Corporation (ADMC). The implementation involved the implementation of cost effective and user-friendly Flamingo DVB to IP gateway solution, as part of the media group’s steps to upgrading its systems by introducing a reliable IPTV service in its headquarter.

As the Middle East’s pioneering multimedia organisation, ADMC has shifted to IPTV in a bid to leverage the advantages of the full-IP approach towards broadcasting. Through the Anevia’s FLAMINGO solution, ADMC can transmit encrypted or free to air digital channels available from satellite channels (DVB-S or DVB-S2), digital terrestrial TV (DVB-T), cable TV (DVB-C) or professional DVB equipment (DVB-ASI) in unicast or multicast mode over an IP network. By using easy-to-install and cost efficient professional DVB to IP gateways, ADMC can benefit from seamless TV channel monitoring and have 24/7 access throughout the building.

"We at Abu Dhabi Media Company always look for best international standards when it comes to Technology Innovations", Abdul Hadi Al Sheikh, Chief Technology Officer at Abu Dhabi Media Company. He also added" We believe that implementing state of art and cutting edge technologies help us in efficiency and effectiveness towards our high quality services and products. The Anevia System will help our News Room and Editorial Team to be up to date watching latest news using IP Protocol Technology."

“IP convergence is fast becoming the trend in the Middle Eastern broadcasting arena, as the region is continuously witnessing a massive technological revolution, which is driving manufacturers to develop modern technologies,” said Jamal Maraqa, Managing Director, PRO TECHnology. “This deployment of Anevia’s Flamingo solution marks the cornerstone for future developments related to site coverage and end-user usage for Abu Dhabi Media Corporation. Through this latest technology in IPTV, ADMC can now provide innovative features for high quality digital video delivery, thereby extending its capability to offer more worldwide TV channels.”

Specialising in the video component of Triple Play – IPTV, VoD, Catch-Up TV and network PVR, Anevia provides services to more than 300 clients across 50 different countries by delivering technologies that facilitate migration to video and TV over IP.

“We are truly looking forward to our partnership with PRO TECHnology to deploy the newest version of our Flamingo DVB to IP gateway solution within ADMC. The services implemented on the existing IP Network combines multiple benefits: ease of use, fast installation on employees’ computers, seamless TV channel monitoring, ubiquitous access throughout the building. Last but not least, it offers reduced costs of deployment. Anevia’s FLAMINGO solution is the cornerstone for future developments related to ADMC site coverage and end-user usage such as VOD, nPVR or Catch-Up TV, which are made available through Anevia’s TOUCAN suite of applications.,” said Mr. Damien LUCAS, co-founder of Anevia.

PRO TECHnology delivers technologies, products and solutions that provide the best IT solutions to both corporate and retail industries. Established in 1998, the company is headquartered in Dubai, UAE and has branches in Jordan, Saudi Arabia, Sudan, Iran and Libya. Presently, PRO TECHnology works with 18 leading international brands in the Middle East and the Levant, including Apple, HP, IBM, Dicota, Qualstar, Nexsan, Storageflex, Maximum Throughput, ENPS, Freecom and Symantec, among others.

Abu Dhabi Media Company
Abu Dhabi Media Company is a vertically integrated media company created in 2007 as a public joint stock company from the assets of Emirates Media Incorporated. Abu Dhabi Media Company employs 1100 people across its operating units which include publishing, television, radio, digital media, distribution, and printing.
Abu Dhabi Media Company owns and operates Abu Dhabi Television, Abu Dhabi Sports Channel, Emirates Television Channel, Abu Dhabi Radio, Emarat FM Radio, Holy Quran Radio, Sawt Al Musiqa, Al Ittihad newspaper, Zahrat Al Khaleej magazine, Al Super magazine and Majid magazine as well as other businesses including United Printing Press.
The company is headquartered in Abu Dhabi with offices in Cairo, Dubai and Washington D.C.

About PRO TECHnology

PRO TECHnology delivers technologies, products and solutions that give the best IT solutions to both Corporate & Retail industries. The company has four distinct lines of business providing unique products and solutions to the respective industry segments such as: Storage, Archiving, Business and Mobility Solutions. Established in 1998, PRO TECHnology is headquartered in Dubai, United Arab Emirates and has branches in Jordan , Saudi Arabia , Sudan, Iran & Libya. PRO TECHnology’s portfolio of world-class brands includes Apple, HP, IBM, Dicota, Qualstar, Nexsan, Storageflex, Symantec/Veritas, Lacie and Canto.
Presently PRO TECHnology works with 18 leading international brands in the Middle East and the Levant and the company’s vision is to collaborate with more powerhouse brands to become a comprehensive, all encompassing solutions provider.

About Anevia

Anevia is a solution provider, specialized in the video component of Triple Play – IPTV, VoD, Catch-Up TV and network PVR. Anevia’s added value lies in its innovative software solution, which combines broadband and television. Anevia's VoD/nPVR TOUCAN servers and DVB to IP FLAMINGO gateways are compact, cheap and easy to deploy.Anevia services more than 300 clients across 50 different countries.
 



 IT | 2008-04-29
Ina chooses Anevia for its transition to IPTV

 

France's Inathèque, the head office of the National Audiovisual Institute in charge of Copyright Registration for Radio and Television, takes a pioneering move by selecting Anevia to broadcast and archive TV channels.

Paris , 29rd April 2008

Anevia, a leading solution provider for video over IP with FLAMINGO DVB to IP gateways and TOUCAN VOD /nPVR servers, today announced that it deployed its innovative products within Ina.

With a 70-year-old experience in TV, 50,000 programmes added each year, 3 million hours archived and receiving a hundred of 24/24 TV channels for copyright registration, Ina becomes a leading company in the field of VOD and TV archiving.

Like major telecom operators, Ina requires first-rate reliability, availability and storage capacity. In this respect, it chose Anevia's expertise to take the technological leap towards quality of service and mass archiving for professional users as well as the general public.

Ina also selected Anevia on the following grounds:

 - reduced investment and servicing costs thanks to a high level of technological integration of Anevia's products: one Anevia FLAMINGO replaces several traditional devices (IRDs and encoders);

- a higher capacity of treatment and optimal archiving: one Anevia FLAMINGO can broadcast up to 60 TV channels at a time;

- a continuous and reliable service thanks to an architecture created for the most demanding telecom operators;

- a smooth transition to full-IP while preserving previous investments.

" Ina's move to IPTV establishes the full-IP approach in the video market. Anevia has been selected for its innovative solution, which meets the need of demanding telecom operators for reliable, easy-to-integrate, and powerful products", said Vincent Meddour, account manager France at Anevia.

About Anevia

Anevia is a solution provider, specialized in the video component of Triple Play – IPTV, VoD, Catch-Up TV and network PVR.

Anevia's added value lies in its innovative software solution, which combines broadband and television.

Anevia's VoD/nPVR TOUCAN servers and DVB to IP FLAMINGO gateways are compact, cheap and easy to deploy.

Anevia services more than 300 clients across 50 different countries.



Life Science | 2008-04-23
Cytheris Announces New Phase I Study of Interleukin-7 As Immunotherapy In Treatment of Bone Marrow or Peripheral Blood Stem Cell Transplant Patients

Clinical trial is designed to investigate use of IL-7 in treatment of
immunodeficient transplant recipients who are vulnerable to a variety of
bacterial, viral, and fungal infections
 
Paris – April 23, 2008 – Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I clinical trial of its lead investigational drug candidate, Interleukin-7 (IL-7), also known as CYT107. This new trial will study the use of IL-7/CYT107 in the treatment of post-transplant patients with T-cell depleted bone marrow or peripheral blood stem cell transplants. The initial study site will be at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City, where Marcel R.M. van den Brink, M.D., Ph.D., Head, Division of Hematologic Oncology, and Miguel-Angel Perales, M.D., Assistant Attending Physician in the Bone Marrow Transplant Service, will serve as Principal Investigator and co-Principal Investigator, respectively. Additional study sites are expected to open in the United States during the coming months.
 
Recombinant human Interleukin-7 (r-hIL-7) is a critical growth factor for immune Tcell recovery and enhancement. Clinical trials conducted on more than 75 patients in Europe, the United States and Canada have suggested the potential of r-hIL-7 to expand and protect CD4+ and CD8+ T-cells. Cytheris is currently conducting multiple international clinical studies of IL-7 in HIV, HCV and cancer.
 
“We share a commitment with MSKCC to addressing the unmet medical need that exists for cancer patients who are frequently in a profoundly immunodeficient state following the bone marrow transplant procedure, leaving them susceptible to a variety of bacterial, viral, and fungal infections,” said Michel Morre, DVM, President and CEO of Cytheris. “MSKCC has for many years been in the forefront of stem cell transplantation therapy in the U.S. and we are therefore especially pleased that Drs van den Brink and Perales have agreed to participate in this study which we hope will ultimately lead to the development of therapies to prevent post-transplant infections which so often contribute to the failure of hematopoietic stem cell allografts .”
 
About the Study
Delayed and deficient reconstitution of T-cell populations and their functions constitute a major obstacle to the success of a hematopoietic stem cell allograft. Experimental studies demonstrate that IL-7 can promote recovery of thymopoiesis, peripheral lymphoid populations and their functions in murine recipients of allogeneic hematopoietic stem cell transplantation (HSCT) without augmenting Graft versus Host Disease (GVHD). Patients admitted to the study must have histologically confirmed non-lymphoid hematological malignancy such as acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), a history of an opportunistic infection (including but not limited to CMV viremia requiring anti-viral therapy), PCP pneumonia, mycobacterial infection, herpes zoster, or viral respiratory infection (influenza, RSV, para-influenza), and have a CD4+ T-cell count < 100 at 2 months post-transplant.
 
The primary objective of the investigation is to determine the safety and a recommended dose of CYT107 in recipients of an HLA-matched related or unrelated ex vivo T-cell-depleted bone marrow or peripheral blood stem cell transplant after initial engraftment and hematopoietic reconstitution. If toxicities are encountered, the study will also seek to establish the maximum tolerated dose (MTD) and dose limiting toxicities (DLT).
 
About Cytheris – www.cytheris.com
Cytheris SA is a privately held clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV and HCV, or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT). The company's lead compound, recombinant human Interleukin-7 (r-hIL-7), is a critical growth factor for immune T-cell recovery and enhancement. Clinical trials
conducted on more than 75 patients in Europe and North America have suggested the potential of r-hIL-7 to expand and protect CD4+ and CD8+ T-cells. The Company is currently conducting multiple clinical studies of IL-7 in HIV, HCV and cancer. The company operates from its headquarters and laboratories in Issy-les-Moulineaux, a suburb of Paris, and its U.S. subsidiary in Rockville, Maryland.



 IT | 2008-04-17
Novaled AG is awarded Red Herring Europe 100 Winner 2008 and announces financial results for 2007

Dresden, Germany. 17th April 2008
 
Novaled, a major know how and service provider for highly efficient long lifetime OLEDs, announces today that the company is winner of Red Herring 100 Europe 2008, an award given to the top 100 private technology companies each year. At the same time Novaled releases the last year’s results proving the enterprises rapid growth.
 
Red Herring’s lists of top private companies are an important part of the publication’s tradition of identifying new and innovative technology companies and entrepreneurs. Novaled has been awarded for its rapid growth and its determining contribution to the organic electronic. Novaled supports Europe’s increasing role as a major center of innovation in the global technology sector.
 
Novaled reached 8.6 Mio. USD* revenue in 2007 showing an impressive growth rate of 67% versus the previous year mainly achieved through material sales and contracted research. With costs of 12.5 Mio. USD the according EBT of 2007 was -3.6 Mio USD.
 
“2007 results showed remarkable growth compared to the global OLED-players”, said Harry Boehme, CFO of Novaled. “The Red Herring Award demonstrates that Novaled is rightly counted among the leading technology companies”.
 
* value €/$ on 31 Dec 07
 
About OLEDs
OLEDs (organic light-emitting diode) are semiconductors made of thin organic material layers of only a few nanometers thickness. They emit light in a diffuse way to form an area light source. In a fast growing display market OLEDs are key part of a revolution: the dream of paper-thin, highly efficient displays with brilliant colors and great flexibility in design is becoming reality. OLEDs represent the future of a vast array of completely new lighting applications. By combining color with shape, organic LEDs will create a new way of decorating and personalizing people’s surroundings with light. At the same time OLEDs offer the potential to become even more efficient than energy-saving bulbs.
 
About Novaled
Novaled AG is a world leading company in the OLED field specialized in high efficiency long lifetime OLED structures and an expert in synthetic and analytical chemistry. The company offers complete solutions to the organic electronic markets, commercializing its Novaled PIN OLEDTM technology along with its proprietary OLED materials.
Novaled has developed long term partnerships with major OLED players worldwide. Based on more than 380 patents granted or pending, Novaled has a strong IP position in OLED technology.
Main investors are Crédit Agricole Private Equity, TechnoStart, TechFund Capital Europe and CDC Innovation. For more details please visit www.novaled.com
 
For further information, please contact:
Novaled:
Anke Lemke, Tel. +49 351 796 5819



 IT | 2008-04-10
La société WIRECOM Technologies accélère son développement et augmente son capital de 4 millions d’euros.

Paris, le 10 avril 2008
 
WIRECOM Technologies, spécialiste de la maîtrise des demandes en énergie par courant porteur, clôt avec succès son second tour de table d’un montant de 4 millions d’euros. Cette augmentation de capital, souscrite par CDC Innovation, SOFIMAC Partners, Emertec Energie Environnement et Centre Capital Développement, va permettre à WIRECOM Technologies d’étendre son offre et de poursuivre son essor. Elle apporte notamment un soutien à la recherche et au développement de l’entreprise et consolide donc son avance technologique.
 
 
A propos de WIRECOM Technologies
WIRECOM Technologies propose depuis sa création des solutions concrètes pour optimiser les dépenses énergétiques du bâtiment et des appareils consommateurs : son système intelligent composé de cartes électroniques permet de faire communiquer entre eux les différents équipements par courant porteur, autrement dit en utilisant le réseau électrique déjà en place. Il assure de réaliser une économie annuelle de 15% à 50% sur la facture énergétique, tout en contribuant à la lutte contre le réchauffement climatique. A ce titre, les solutions de WIRECOM Technologies s’inscrivent parfaitement dans la démarche des Grenelles de l’Environnement et des constructions durables.
 
Preuve de l’efficacité et de la fiabilité de ses solutions, WIRECOM Technologies a installé en moins de 2 ans plus de 75 000 cartes sur 10 000 bâtiments. Son système est aujourd’hui référencé dans de nombreux sites de prestige comptant parmi ses clients et partenaires des entreprises de renom telles que CARI, Bouygues Construction, EDF, POWEO, L’Oréal,  ...
 
L’opération de capitalisation permettra à WIRECOM Technologies de :
·          proposer des solutions aux particuliers ;
·          étendre sa gamme de produits intégrés dans les équipements électriques ;
·          conserver son avance technologique en poursuivant son investissement en recherche et développement ;
·          apporter toujours plus de services ;
·          répondre aux demandes croissantes du marché ;
·          renforcer son réseau commercial ;
·          s’imposer comme leader sur le marché de la maîtrise des énergies au niveau international
 
Couplé à cette hausse de capital, WIRECOM Technologies a également racheté sa grande sœur ISI SYSTEMS. Cette société spécialisée dans le développement informatique industriel, et créée en 1997 par Thierry Allard est notamment à l’origine du concept de WIRECOM Technologies. Elle développe et met en service la supervision et le contrôle commande pour optimiser l’exploitation de systèmes. En rejoignant WIRECOM Technologies, ISI devient le service ingénierie de WIRECOM et lui apporte des compétences supplémentaires en automation et supervision.
 
WIRECOM Technologies se donne les moyens de répondre aux besoins grandissants du marché et de la planète, et de poursuivre sa croissance exponentielle. C’est avec satisfaction qu’elle accueille le soutien de ses investisseurs.
Contact : Thierry Allard - Tél. : +33 (0)2 36 56 86 00 - tallard@wirecom-tech.com
 
 
 
 
 
 
 
 
 
 
 
A propos de CDC Innovation
CDC Innovation est une société internationale de venture capital avec son siège à Paris et une présence locale dans la Silicon Valley et en Suisse. Avec plus de 415M€ de fonds sous gestion, elle investit dans des entreprises innovantes en phase de croissance dans deux secteurs : les technologies de l’information et les sciences de la vie. Son objectif est de créer de la valeur en apportant à des entrepreneurs de talent les ressources, l’expérience et le réseau nécessaires pour transformer des sociétés technologiques à haut potentiel en de véritables succès industriels.
Pour plus d’information, consultez le site : www.cdcinnovation.com
Contact : Bertrand Limoges - Tél. : +33 (0)1 40 76 99 16 - bertrand.limoges@cdcinnovation.com
 
A propos de Emertec Énergie Environnement
Le fonds Emertec Energie Environnement (fcpr 3E), géré par Emertec Gestion est dédié au financement de sociétés en phase d’amorçage dans le secteur de l’énergie et de l’environnement. Cet investissement est le cinquième du fonds qui devrait compter d’ici 2008 une dizaine de participations dans ce secteur en forte croissance.
 
Contact : Eric Marty – Tél. : +33 (0) 4 38 12 38 99 - emarty@emertec.fr
 
A propos de Sofimac Partners
Depuis sa création en 1977, SOFIMAC Partners est spécialiste des métiers de l’investissement dans les entreprises non cotées et s’adresse principalement aux PME de l’Espace Central. Elle vise à les accompagner à tous les stades de leur développement. SOFIMAC Partners gère un total de 70 millions d’euros. Elle dispose, à travers ses différents véhicules d’investissement, d’un portefeuille de 70 sociétés, de tous secteurs industriels et technologiques, et investit dans près de 10 entreprises par an.
 
Contact : Pascal Voulton – Tél :+33 (0)4 73 74 57 57 - p.voulton@sofimacpartners.com
 
A propos de Centre Capital Développement
Créé en 1987 à l’initiative d’acteurs économiques régionaux, Centre Capital Développement a pour vocation d’accompagner le développement des entreprises de la région Centre par l’apport de Fonds Propres. Investisseur de proximité, Centre Capital Développement agit en partenaire actif des PME/PMI régionales lors d’opérations de croissance interne ou externe, d’innovation technologique, de conquête de marchés nouveaux, de reprises d’entreprises. Centre Capital Développement est aujourd’hui présente au capital d’une quarantaine de PME/PMI des secteurs de l’industrie, des services à l’industrie et du commerce de gros de la région Centre.
 
Contact : Jean-Louis Lemarchand – Tél : +33 (0)2 38 78 18 15 - ccd@centcdev.com



 Life Science | 2008-04-09
Novagali Pharma announces the launch of Cationorm®

• The innovative cationic emulsion for the treatment of dry eye symptoms
• An optimal solution for patients
• The first product developed from its pipeline to be marketed.
 
 
EVRY (France) - April 9th, 2008 - Novagali Pharma, an ophthalmic specialty pharmaceutical company announces the commercial launch in France of its first product Cationorm®. This cationic emulsion is an innovative approach to treat dry eye symptoms. It has been developed on the basis of Novagali Pharma patented technology platform Novasorb®.
 
Dry eye syndrome is the second cause of consultation in ophthalmology. It concerns over 100 million people in the world and 14 % of the adults of more than 40 years. Due to a chronic lack of lubrication and moisture in the eye, its consequences range from irritation to ocular inflammation of the conjunctiva and corneal tissues of the eyes. People with dry eye have sandy-gritty irritation or burning in their eyes. In most severe cases, corneal lesions may lead to vision loss. Specific factors such as ageing populations, pollution, air conditioning, extended use of computers, contribute to an increase in the prevalence of the syndrome and in opportunities for the development of more efficient products.
 
Cationorm® brings a true innovation to the patients suffering from dry eye symptoms. The cationic emulsion reproduces the tear mechanisms of action to act on the different levels of the tear film. Cationorm® uniquely combines lubricating and hydrating properties, optimal spreading on the surface of the eye, replenishment of the tear film lipid layer and prevention of tear evaporation. The results of clinical study have clearly demonstrated Cationorm® advantages for patients: tolerance, long-lasting relief and optimal comfort.
 
These advantages are based on Novasorb®, the proprietary cationic emulsion technology platform of Novagali Pharma. Novasorb®, is designed to improve topical administration of ophthalmic medicines. It is based on the electrostatic attraction that occurs between the droplets of a positively-charged emulsion and the negatively charged cells of the ocular surface, including cornea and conjunctiva.
 
The commercial launch of Cationorm® in Europe and in the United States by the end 2008, where the product complies with the OTC status, is a major event for the development of Novagali Pharma. « Cationorm® commercial launch is very special to us being our first marketed product coming out of our pipeline. It is the result of many years of work for the entire Novagali team and we are very proud of the innovation Cationorm® brings for the treatment of dry eye symptoms » , said Jérôme Martinez, CEO of Novagali Pharma.
 
Cationorm® is a medical device available in France since April 2008. The product is unpreserved and packaged in box of 30 sterile single vials.
 
A propos de Novagali Pharma : http://www.novagali.com
 
Novagali Pharma is an ophthalmic pharmaceutical company based in the Génopôle biocluster in Evry (France) that develops and commercializes innovative products. Thanks to its proprietary technology platforms Novasorb® and Eyeject®, the company has developed a broad pipeline of 7 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia®, an orphan product for treatment of vernal keratoconjunctivitis, Cyclokat®, a product for the treatment of moderate-to-severe dry eye syndrome and Cortiject® for the treatment of diabetic retinopathies. Cationorm®, indicated for dry eye symptoms is commercialized in France since April 2008. Founded in 2000, Novagali Pharma has 50 employees.



 Life Science | 2008-03-27
SCYNEXIS, Inc. Completes $13.5 Million Financing

Research Triangle Park, N.C., March 27, 2008 - SCYNEXIS, Inc. a premier drug discovery and development company, today announced the successful completion of a $13.5 million Series C-2 financing. The financing was led by Merial Limited, a joint venture between Merck & Co., Inc. and sanofi-aventis. SR One, GlaxoSmithKline’s independent corporate healthcare venture capital fund, also participated.
 
In 2005, SCYNEXIS was selected as the primary research partner for Merial, a world-leading animal health company, in an agreement that included up to $150 million in research funding and additional undisclosed milestone and royalty payments. This collaboration was expanded in May of 2007 and in December of 2007 SCYNEXIS received its first milestone payment. SR One initially invested in SCYNEXIS in the Company’s Series C round in 2002.
 
"SR One is pleased to be a part of the continuing development of SCYNEXIS and the progress of its portfolio," said Philip L. Smith, Ph.D. and General Partner, SR One Ltd.
“It is tremendously validating when current collaborators and investors demonstrate continued commitment,” said SCYNEXIS President and CEO Dr. Yves J. Ribeill. “We are extremely pleased with Merial and SR One’s confidence in both our growth potential and in the role SCYNEXIS will play discovering and developing human and animal therapeutics, including new treatments for neglected diseases.”
 
“As an innovation-driven animal health company, Merial’s long collaboration with SCYNEXIS has greatly enhanced our ability to identify and optimize novel active compounds that will form the basis for new products to meet our customers’ needs and to maintain our competitive advantage,” said Jose Barella, Merial’s Executive Chairman. “We are pleased to take this next step in the expansion of our relationship.”
 
About SCYNEXIS

SCYNEXIS is a premier drug discovery and development company delivering effective and innovative drug pipeline solutions to pharmaceutical and global health partners. The Company is also focused on developing a proprietary internal pipeline based on cyclophilins, a class of drugs that hold significant potential for the treatment of a broad range of diseases.


About Merial Limited

Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs more than 5,000 people and operates in more than 150 countries worldwide. Its 2007 sales were nearly $2.5 billion. Merial Limited is a joint venture between Merck & Co., Inc. and sanofi-aventis. For more information, please see www.merial.com.


About SR One
 
SR One is GlaxoSmithKline’s independent corporate healthcare venture capital fund. Based in Conshohocken, PA, and London, U.K., SR One invests globally in emerging biotechnology companies that are engaged in drug discovery, development and delivery with the potential to yield dramatic patient benefits. Since its founding in 1985, SR One has placed over $500 million in more than 150 investments. For more information on SR One, its staff and portfolio companies, please visit www.srone.com.



 IT | 2008-03-19
Novaled opens its first subsidiary in Asia

03/19/2008
 
Novaled, a major OLED know how and service provider reinforces its presence in the Asian market by opening a Japan Branch office.
 
Effective from 10th March 2008, Novaled set up a Branch Office in the Tokyo area. With this new opening, the company confirms its commitment to the OLED industry in Asia. The Novaled Branch office will contribute to further improve the service and support to existing customers, sustain the running cooperations and partnerships, and develop the company activities in the organic electronic field where the doped organics technology of Novaled is expected to play a key role.
 
“Novaled places service to customers as its first priority and wants to be in close proximity to them”, says Gerd Guenther, VP Marketing & Sales of Novaled AG.
 
“Japan remains a major center for the OLED industry and can play an important role in the fast emerging organic electronics markets”, adds Yoichi Kadota, Novaled Country Manager Japan. “We have the proper technology to support these industry moves”.
 
The Novaled Japan Branch office is accommodating a technology support service, aimed at providing first and fast reacting technical help to its Asian customers. Philipp Wellmann, Novaled Asia Customer Support Manager, is carrying out this service located in the Novaled Japan office.
 
About OLEDs

OLEDs are semiconductors made of thin organic material layers of only a few nanometers thickness. They emit light in a diffuse way to form an area light source. In a fast growing display market OLEDs are key part of a revolution: the dream of paper-thin, highly efficient displays with brilliant colors and great flexibility in design is becoming reality. OLEDs represent the future of a vast array of completely new lighting applications. By combining color with shape, organic LEDs will create a new way of decorating and personalizing people’s surroundings with light. At the same time OLEDs offer the potential to become even more efficient than energy-saving bulbs.
 
About Novaled

Novaled AG is a world leading company in the OLED (organic light-emitting diode) field specialized in high efficiency long lifetime OLED structures and an expert in synthetic and analytical chemistry. The company offers complete solutions to the organic electronic markets, commercializing its Novaled PIN OLEDTM technology along with its proprietary OLED materials. Novaled has developed long term partnerships with major OLED players worldwide. Based on more than 350 patents granted or pending, Novaled has a strong IP position in OLED technology. Main investors are Crédit Agricole Private Equity, TechnoStart, TechFund Capital Europe and CDC Innovation. For more details please visit www.novaled.com.



 IT | 2008-03-14
Nemoptic invited to demonstrate its A4 e-paper display at the International Book Fair in Paris

Magny les Hameaux, France, March 14, 2008 — Nemoptic, an e-paper display company for consumer and professional handheld devices, announced today that the French Publishers’ Association has invited the company to demonstrate its high resolution A4 BiNem® e-paper display in the International Book Fair in Paris, March 14 – 19.

In addition to bringing together authors from around the globe for visitors to meet, the Paris Book Fair has organized a series of workshops to allow attendees to discover the technologies that could impact on the reading of books in the future. Nemoptic will present its A4 e-paper document in the session on “Tomorrow’s Reader”. This session is made up of four segments covering digital media:
-      E-books and electronic ink
-      Mobile handheld devices (PSP, PDA, and other devices)
-      Knowledge (digital libraries, the Gallica project, the electronic satchel/book bag)
-      Digital data
 
“The inclusion of e-paper technology presentations at the Paris Book Fair is a strong reflection of the growing interest in new reading forms,” explained Jacques Noëls, CEO at Nemoptic. “We are pleased that the French Publishers’ Association has chosen our A4 BiNem e-paper display in recognition of the quality and potential of our products.“
 
“Nemoptic’s A4 e-paper display truly offers excellent reading quality. We are very happy to show the Paris public new products in new formats; it gives a real idea of what reading could look like in the future, and even more happier that it is French innovation, too.” said Minh Son Nguyen, co-organizer of the “Tomorrow’s Reader” workshop.
 
Nemoptic’s black & white A4 BiNem e-paper display has a high image quality, enabling excellent readability that is comparable to print on paper. Users can benefit from its low power consumption, as the device does not use power except for image changes.
 
It offers a resolution of 200 dpi, among the highest in the market, has 1650 x 2340 pixels, a screen refreshing time of less than 1 second, and is less than 2mm thick. Display brightness is above 30 per cent.
 
The A4 BiNem display expands Nemoptic’s e-paper product portfolio, which now ranges from 3 inch Electronic Shelf Labels to A4 size. The range covers e-paper display sizes such as 4.5" for e-dictionaries and A7 for e-books and e-newspapers, as well as other prototyping and evaluation kits dimensions.  
 
Since the signing of Nemoptic’s manufacturing deal with Seiko Instruments Inc., last year, all of Nemoptic’s BiNem e-paper displays are available in high volume.
 
  
About Nemoptic
Nemoptic is an e-paper (electronic paper) display company that designs and manufactures superior-quality bistable liquid crystal display (LCD) modules highly suitable for consumer and professional mobile devices.
 

Unlike other e-paper LCDs in the market, Nemoptic offers a white screen, giving users the best image contrast and a remarkable screen reading experience, comparable to ink on paper. The company’s cutting-edge technology, BiNem® (Bistable Nematic), has applications in electronic shelf labels, point–of-purchase (POP) systems, home automation and in a range of handheld devices including e-books, e-newspapers, ultra mobile PCs, and mobile phones. Nemoptic e-paper displays are recognized for their high resolution, zero-power consumption when holding images and low manufacturing cost. They come in pure black and white, gray scale and offer a large number of colors. BiNem displays also come in bendable versions. Nemoptic is headquartered in France near Paris, operates a pilot production unit in Sweden, and runs its mass production from Seiko Instruments Inc.’s (SII) facilities in Japan. Please visit: www.nemoptic.com



 IT | 2008-03-05
TxCell completes a €10.5 million second round and initiates clinical trials

Sophia Antipolis, March 5th, 2008 – TxCell, a specialty biopharmaceutical firm developing novel cell therapies for autoimmune and chronic inflammatory diseases, today announced that it had raised €10.5 million in a second round of financing. In 2007, the AFSSAPS (the French Agency for Health Product Safety) authorized the company to start its first clinical trial of a Tr1 lymphocyte-based therapy in Crohn’s disease. This round of financing confirms the significant potential of TxCell’s innovative approach and will enable the company to determine the clinical efficacy of treatment with autologous Tr1 cells.
 
This second round, led by TxCell’s longstanding investors Auriga Partners, AXA Private Equity, Bioam Gestion, CDC Innovation and Seventure, will allow the company to progress its development programs on Crohn’s disease (OvasaveTM), rheumatoid arthritis (CellArthrixTM) and a number of orphan diseases.
 
“This fundraising testifies to the confidence that TxCell’s longstanding investors have placed in our company and confirms the great potential of this cell therapy approach (based on the biological properties of Tr1 regulatory lymphocytes) for the treatment of autoimmune and chronic inflammatory diseases”, commented Frédéric Hammel, CEO of TxCell.
 

For more information on the company please visit:
www.txcell.com



 IT | 2008-03-04
Ciba develops long-lifetime phosphorescent material for Novaled’s OLED technology

Dresden, Germany. 4th March 2008
  • Red phosphorescent emitter functions optimally with Novaled’s proprietary technology for highly power-efficient OLEDs
  • Delivers lifetime of 50,000 hours at initial brightness of 1,000 cd/m2
  • Supports market trend toward high-performance, low-voltage OLED devices
Ciba has developed a deep red phosphorescent OLED emitter that functions optimally in combination with the Novaled PIN OLED™ technology, delivering a lifetime of 50,000 hours at an initial brightness of 1,000 cd/m2. The new material supports the market trend toward high-performance, low-voltage OLED devices for display and lighting applications.
 
"We want to provide the market with efficient phosphorescent materials," says Rolf Drewes, Global Head of Business Line Electronic Materials at Ciba. "In this project, we are developing the full color range of emitters compatible with Novaled’s proprietary OLED technology. Our deep red, the first to become commercially available, offers customers not only long-lifetime performance but also excellent thermal stability. Green and blue are now in progress."
 
"Phosphorescent emitter materials together with low-voltage devices are mandatory for the future of the OLED industry, and Novaled is very pleased to see a key industry player developing such materials," adds Gildas Sorin, CEO of Novaled AG. "This deep red phosphorescent material provides a long lifetime at a lowest operating voltage of 3.3 V as well as good power efficiency of 8.1 lm/W, making it suitable for displays as well as for completely new lighting applications. OLED technology even has potential to surpass the efficiency of energy-saving bulbs."
 
Made of thin organic material layers only a few nanometers thick, OLEDs are semiconductors that emit light in a diffuse way to form an area light source. In 2006, Ciba and Novaled entered an industrial collaboration to create organic dopant and transport materials for the Novaled PIN OLED™ technology, which enables highly power-efficient OLED performance.
 
Novaled AG is a world-leading company in the OLED (organic light-emitting diode) field specialized in high efficiency, long-lifetime OLED structures and an expert in synthetic and analytical chemistry. The company offers complete solutions to the organic electronic markets, commercializing its Novaled PIN OLED™ technology along with its proprietary OLED materials. Novaled has developed long-term partnerships with major OLED players worldwide. Based on more than 350 patents granted or pending, Novaled has a strong IP position in OLED technology. For more information, visit www.novaled.com.
 

Ciba (SWX: CIBN) is a leading global company dedicated to producing high-value effects for its customers’ products. We strive to be the partner of choice for our customers, offering them innovative products and one-stop expert service. We create effects that improve the quality of life – adding performance, protection, color and strength to plastics, paper, automobiles, buildings, home and personal care products and much more. Ciba is active in more than 120 countries around the world and is committed to being a leader in its chosen markets. In 2007, the Company generated sales of CHF 6.5 billion from continued operations and invested over CHF 260 million in R&D.



 IT | 2008-03-03
CDC Innovation et EI-Capital acquièrent les sociétés Groupe Critères et AVS Consulting au sein de Entrepreneurs et Investisseurs Technologies

 

Paris, le 3 mars 2008 –CDC Innovation et Entrepreneurs & Investisseurs Capitalannoncent la création d’Entrepreneurs et Investisseurs Technologies (« EI-Technologies »). Ils ont pour objectif commun de bâtir un groupe de spécialistes à forte valeur ajoutée dans les domaines les plus innovants du conseil et des services en systèmes d’information, en procédant par acquisitions et par croissance interne.
 
EI-Technologies a acquis, le 1er février 2008, les sociétés Groupe Critères et AVS Consulting.
 
Groupe Critères est un des leaders indépendants de l'industrie du test logiciel. Il intervient, depuis de nombreuses années, dans l'évaluation, l'amélioration et le développement des processus de test d’applications informatiques ainsi que dans leur exécution.
 
AVS Consulting, société de conseil et de services experte en nouvelles technologies, a développé un savoir-faire reconnu dans la mise en œuvre de progiciels de gestion de la relation client sous forme de service à la demande (On Demand CRM). Il est ainsi devenu le premier partenaire en France de l’éditeur « Salesforce », l’un des leaders mondiaux du On Demand CRM.
 
Après une croissance de son chiffre d’affaires supérieure à 30% en 2007, l’ensemble des deux sociétés nouvellement acquises vise un chiffre d’affaires pour l’année 2008 dépassant les 10 millions d’euros. CDC Innovation et EI-Capital ont investi respectivement 2,8 M€ et 1,2 M€ dans l’opération.
 
Bechara Raad, PDG de EI-Technologies, déclare : « Le choix de CDC Innovation comme partenaire nous donne les moyens de réaliser notre ambitieux projet de développement dans le secteur. »
 
Franck Noiret, General Partner de CDC Innovation, déclare : « Nous sommes particulièrement heureux de nous associer à une équipe de management expérimentée. La pertinence de sa stratégie ainsi que l’attractivité des segments technologiques ciblés représentent un fort potentiel de création de valeur. »
 
 
 
 
Contacts:
 
EI-Technologies : Bechara RAAD - Tél. : 01 42 68 50 91
 
CDC Innovation :Franck NOIRET - Tél. : 01 40 76 99 04
 
 
 
A propos de CDC Innovation 
 
Créée en 1996, CDC Innovation est une société internationale de venture capital avec son siège à Paris et une présence locale dans la Silicon Valley et en Suisse.
Avec plus de 415 M€ de fonds sous gestion, elle investit dans des entreprises innovantes en phase de premiers développements ou en phase de croissance, dans deux secteurs: les technologies de l'information et les sciences de la vie.
Son objectif est de créer de la valeur en apportant à des entrepreneurs de talent les ressources, l'expérience et le réseau nécessaires pour transformer des sociétés technologiques à haut potentiel en de véritables succès industriels.
 
Pour plus d’information, consultez le site: www.cdcinnovation.com
 
 
A propos de EI-Capital
 

Créée en 2007 par Bechara RAAD, Jean-Arnaud de LASA et Pierre SARROLA, Entrepreneurs & Investisseurs Capital est une société d’investissement spécialisée dans l’acquisition de PME en transmission. Elle élabore aujourd’hui deux regroupements sectoriels, le premier dans le domaine du conseil et des services en systèmes d’information, le second dans la fourniture de solutions technologiques pour l’immobilier.



 IT | 2008-03-03
Le français TES rachète le centre de conception Assystem de Quimper

Le sous-traitant en conception et fabrication TES Electronic Solutions vient de racheter à la société d'ingénierie et de conseil en innovation Assystem, un centre de conception basé à Quimper. Fort de trente employés, ce bureau d'études est spécialisé en conception mécanique, plastique et d'habillage, en qualification de produits, ainsi qu'en conception de produits RF (notamment téléphones DECT et GSM) et en acoustique (le centre est doté d'un laboratoire d'analyse acoustique utilisé en particulier pour tester les téléphones et les microphones). Ce laboratoire devrait monter en puissance : ''le nombre d'employés devrait augmenter de 50% d'ici à six mois et devrait doubler d'ici à un an'', nous a ainsi indiqué Nick Walker, senior vice président, directeur des ventes et du marketing de TES. Avec quelque 850 salariés (dont la moitié en conception), TES a, l'an passé, réalisé un chiffre d'affaires de 100 millions d'euros, en progression de 5% par rapport à 2006. La société a réussi sa diversification. Pour 2008, elle prévoit une hausse de 20% de ses ventes.



 Life Science | 2008-02-13
Cytheris Announces 48-Week Results of Phase I/II Study Showing Administration of Interleukin-7 (IL-7) Significantly Improves CD4 T-Cell Counts in Chronically Infected HIV-1 Patients

Additional Results From Two Non-Human Primate Studies Indicate IL-7
Administration May Provide Therapeutic Route To Stable Disease
Paris – February 13, 2008 – Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced results of the long-term follow-up of patients in a multi-center Phase I/II study designed to investigate the safety of Interleukin-7 (IL-7) therapy in chronically HIV-1 infected patients whose CD4+ T-cell counts remained low despite treatment with anti-retroviral-therapies (HAART). After 48 weeks, patients treated at the higher dose level showed a median increase in CD4+ and CD8+ T-cell counts (cells/μL) of 75% and 57%, respectively, from baseline levels. Additionally, two posters detailing non-human primate studies of IL-7 immunotherapy and early T-cell homing to the gut were presented at the 2008 Conference on Retroviruses and Opportunistic Infections (CROI) held last week in Boston.
 
The results of the Phase I/II long-term follow-up study (Abstract #708) were presented by Pr. Yves Lévy MD, PhD (Hôpital Henri Mondor, Créteil, France and INSERM), Principal Investigator. This long-term follow-up investigation indicates the stability of the T-cell response already noted at week 12 of the study and previously reported by Dr. Lévy at CROI in 2007.
 
“In the long-term follow-up of this study, IL-7 administration significantly improves CD4 T-cell counts in patients who entered the study with low CD4 counts, opening them to potentially fatal opportunistic infections,” said Dr. Michel Morre, President and CEO of Cytheris. “If we can restore normal levels of CD4 in these HIV-infected patients undergoing HAART therapy, IL-7 may then become an important therapeutic option in the treatment of HIV as a chronic disease, allowing these patients to potentially achieve a normal lifespan. These results thus reinforce interest in continuing clinical investigation of IL-7 for treatment of HIV infection.”
 
48-Week Results of Phase I/II Study
 
The hallmark of HIV infection is a defect in the function and homeostasis of CD4+ T lymphocytes leading to the development of opportunistic infections and malignancies. IL-7 plays multiple roles in the differentiation, expansion and survival of T-cells. Studies in animal experimental models have shown that IL-7 can enhance the proliferation and expansion of T lymphocytes. By its action, IL-7 may provide a novel approach for the restoration and/or improvement of the CD4+ T-cell pool and immune functions in patients infected with HIV.
 
The Phase I/II trial was designed to investigate the safety of IL-7 therapy in chronically HIV-1 infected patients with low CD4 counts (100-400 CD4+/μl) and plasma HIV RNA <50 cp/ml for at least 6 months while on HAART. Six and 7 patients were included in the first (3 μg/kg) and second (10 μg/kg) dose level, respectively. Patients received 8 subcutaneous injections (3 times/week; days 1-16) of r-hIL-7. Clinical, biological and virological safety parameters were monitored until week 48. HIV Gag-specific T-cell responses were assessed by intra-cellular cytokine staining in the 10 μg/kg group.
 
The long-term results for this group of patients, defined as “immune non-responders”, indicate that the IL-7 induced rapid expansion of CD4+ and CD8+ T-cell counts was sustained up to 48 weeks from study entry. Importantly, 48 weeks after initiation of this IL-7 short course of treatment, patients treated at the 10 μg/kg dose level showed a median increase in CD4+ and CD8+ T-cell counts (cells/μL) of 75% and 57%, respectively, from baseline levels.
 
Results of Non-Human Primate Studies
 
The IL-7 induced T-cell proliferation indicated in the long-term follow-up to the Phase I/II study discussed above is now broadly confirmed by numerous studies in nonhuman primates such as the two poster presentations discussed here. These studies were conducted in collaboration with the Seattle Biomedical Research Institute (SBRI), the Vaccine and Gene Therapy Institute (VGTI) and the Oregon National Primate Research Center (ONPRC) at Oregon Health and Science University, Emory University (Abstract #707) and the Institut Pasteur, Paris (Abstract #709).
 
These two studies were designed to analyze the potential of IL-7 treatment to facilitate reconstitution in the deep lymphoid tissues such as lymph nodes and G.I. tract. In both human HIV and simian SIV infection it has been shown that CD4+ T-cell depletion occurs quickly and primarily in the gut. Of particular note is that in these simian models, “elite controllers” (ECs), rare individuals who spontaneously control HIV viremia to levels below the detection threshold of current assays, consistently show good T-cell repopulation of the gut. In these two studies, not only did IL-7 confirm its potential for T-cell expansion, but it also showed its ability to send T-cells to the gut mucosa where it also triggers local T-cell expansion. Numerous experimental and clinical studies have shown that T-cell reconstitution in the gut is critical for restoring control over the HIV virus.
 
Summary of Presentation Results
 
These findings based on animal models and human studies emphasize the potential stability of the IL-7 effect on the production of T-cells over time as well as its possible impact in stimulating T-cell proliferation in the lymphoid tissue layer in the mucous membrane of the GI tract.
 
 
Taken together, these studies suggest that administration of IL-7 may have an important effect on immunologic recovery in HIV-infected patients whose HAART regimens have been unsuccessful in restoring CD4+ T-cells to a stable level. These “Immune Non Responders,” patients with progressive or unstable disease, are in marked contrast to nonprogressors or “elite controllers” who, like their simian counterparts noted above, show no evidence of HIV progression and have stable CD4+ T-cell counts even after years of HIV infection. The sustained immunological efficacy seen in the long-term follow-up of the Phase I/II study suggests that a short course of IL-7 treatment may provide an important avenue for enhancing the immune system and inducing broad spectrum proliferative activity of CD4+ and CD8+ T-cells in the blood, lymph nodes and small intestine, a key therapeutic effect in achieving long term disease stability in HIV-infected patients.
 
About Cytheris – www.cytheris.com
Cytheris SA is a privately held clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV and HCV, or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).
 
The company's lead compound, recombinant human Interleukin-7 (r-hIL-7), is a critical growth factor for immune T-cell recovery and enhancement. Clinical trials conducted on more than 60 patients in France and the U.S. have already demonstrated the ability of r-hIL-7 to expand and protect CD4+ and CD8+ T-cells. The Company is currently conducting multiple clinical studies of IL-7 in HIV, HCV and cancer.
 
A second family of products being developed by the company is based on highly potent NKT/dendritic cell ligands in-licensed from New York University, the Aaron Diamond AIDS Research Center and the City University of New York. NKT cells have been implicated in many diverse aspects of immunity, including regulation of autoimmune disorders, control of tumor growth and spread, and defense against a number of pathogens. The product family strengthens innate and adaptive immunity connections and will provide new immuno-therapeutic adjuvants for cancer and chronic infectious diseases.
 

The company operates from its headquarters and laboratories in Issy-les-Moulineaux, a suburb of Paris, and its U.S. subsidiary in Rockville, Maryland.



 IT | 2008-02-13
Lancement d’IWEDIA Services : Une offre unique de conseil et d’ingénierie dédiée à la télévision et à la vidéo numérique

Rennes, le 13 février 2008 : Patrick Desproges, Président du Directoire du Groupe IWEDIA, a annoncé aujourd’hui le lancement d’une nouvelle division de conseil et d’ingénierie dédiée aux technologies de télévision et de vidéo numérique.
 
"Nous lançons aujourd’hui IWEDIA Services sur des objectifs de croissance ambitieux : le doublement de l’activité en trois ans. Objectifs ambitieux mais réalistes eu égard à son positionnement unique sur le marché de la télévision et de la vidéo numérique", a déclaré Patrick Desproges.
 
IWEDIA Services regroupe l’expérience et le savoir faire accumulés depuis plus de dix ans par les équipes de l’activité consulting d’IWEDIA et de Westcast, société spécialisée dans les technologies de streaming sur Internet, intégrée au Groupe IWEDIA en 2005.
 
Pour Dominique Villotte, Directeur Général d’IWEDIA Services, "Notre offre est parfaitement adaptée aux acteurs de la chaîne de valeur de la télévision et de la vidéo numérique : fournisseurs de contenus, opérateurs broadcast, broadband et mobile, équipementiers, fabricants de terminaux, etc.. Sur ce marché spécifique, la gamme de nos prestations est très large et nous apportons de la valeur ajoutée à tout moment du cycle de vie des projets de nos clients. Il peut s’agir par exemple de participer très en amont à la conception d’un nouveau service ou d’un nouveau terminal. Ou d’intervenir pendant la phase de tests et de validation d’un terminal pour définir les campagnes et les exécuter. Ou bien encore de prendre en charge, en assurant un guichet unique, la maintenance logicielle d’un parc de terminaux."
 
"L’expertise, le savoir faire et le professionnalisme de nos consultants sont déjà reconnus par un grand nombre d’acteurs industriels (tels Thomson, Philips, Cisco, Sagem ou Viaccess), d’opérateurs de services et de fournisseurs de contenus (tels CANAL+, Numericable, l’Equipe TV ou Sporever). Notre offre réorganisée en lignes d’expertise va nous permettre d’accompagner mieux encore ce marché et de participer à son développement", précise Dominique Henninot, Directeur Commercial et Marketing d’IWEDIA Services.
 
-  -
A propos d’IWEDIA
 
Preparing tomorrow’s television together.
 
Le Groupe IWEDIA est à la fois éditeur de logiciels pour terminaux numériques audiovisuels connectés (division IWEDIA Middleware) et fournisseur de services de conseil et d’ingénierie aux acteurs de la chaîne de l’image (division IWEDIA Services). Implantée à Rennes et à Issy-les-Moulineaux, IWEDIA capitalise sur une expérience de plus de dix ans en télévision et en vidéo numérique. Naturellement innovante, IWEDIA participe pro activement au Pôle de Compétitivité à vocation mondiale "Images & Réseaux". Société indépendante, IWEDIA est soutenue par quatre sociétés de capital risque actives dans le secteur des médias numériques : ACE Management, CDC Innovation, I-Source et iXCore.



 Life Science | 2008-02-12
Phase III program for AVE0010/ZP10 licensed from Zealand Pharma A/S will begin in the first quarter of 2008.

Copenhagen, 12 February 2008
 
Today Sanofi-Aventis announced that after consultation with the healthcare authorities, the Phase III program for the GLP-1 agonist AVE0010/ZP10 licensed from Zealand Pharma A/S will begin in the first quarter of 2008.
 
The program will include over 3,000 diabetic patients and will evaluate a once-a-day injection of AVE0010/ZP10 in combination with the principal existing treatments (metformin, sulfonylurea, insulin), as well as a comparison with exenatide and a monotherapy study.
 
Filing for approval is expected in 2010. A prolonged release formulation is currently being evaluated in Phase I.
AVE0010/ZP10
AVE0010/ZP10 is a glucagon-like peptide 1, or "GLP-1", receptor agonist developed for subcutaneous injection treatment of Type 2 Diabetes and incorporates Zealand Pharma's "SIP" technology. The compound was licensed to Sanofi-Aventis in 2003.
 
Endogenous GLP-1 is released from the small intestine in response to food intake and stimulates insulin liberation from the pancreas when blood sugar levels are elevated. In addition, GLP-1 suppresses the production of glucagon (a hormone produced in the pancreas that signals the liver to release stored sugar into the bloodstream) as well as reduces appetite and delays food absorption. GLP -1 only stimulates the release of insulin in case of elevated blood sugar levels but not during periods of normal or low blood sugar. This unique mechanism is associated with a lower risk of hypoglycemia (low blood sugar levels) than conventional antidiabetic drugs.
 
In the second half of 2007, Sanofi-Aventis successfully completed their double blind, placebo controlled Phase II dose ranging study for AVE0010/ZP10 in 500 Metformin treated patients with Type 2 Diabetes, meeting their primary endpoint of a reduction of the HbA1C levels at the end of treatment.
 
In line with observations from treatment with AVE0010/ZP10 for up to 28 days, once daily dosing with doses that produced marked lowering of HbA1c during 13 weeks of treatment were associated with low incidence of nausea. In addition, treatment with AVE0010/ZP10 was associated with significant weight loss in obese diabetic patients.
Type 2 Diabetes
 
Insulin is a naturally occurring, or endogenous, protein that is produced in the pancreas and is essential for uptake of blood sugar into the cells.
 
In patients with Type 2 Diabetes, often referred to as adult onset diabetes, cells become less sensitive to insulin. Moreover, in late stages of the disease, the pancreas loses the ability to produce sufficient insulin. Type 2 Diabetes is the most common form of diabetes and is caused by both genetic and environmental factors, such as obesity. As a result, the blood sugar is not sufficiently controlled.
 
If Type 2 Diabetes is not successfully treated, the patient will ultimately develop severe complications such as stroke, heart attacks, heart failure, kidney failure, blindness and disorders in peripheral nerves.
 
Current medical treatment is capable of controlling blood sugar during the first years after onset of Type 2 Diabetes but as the disease progresses, the existing therapy provides inadequate protection against diabetic complications. Consequently there is a strong need for an alternative treatment of Type 2 Diabetes and AVE0010/ZP10 belongs to the new class of GLP-1 compounds, which are expected to delay the progression of the disease.
 
According to the International Diabetes Foundation, approximately 246 million people globally had diabetes in 2007. Type 2 Diabetes represents 85-95% of all cases of diabetes in the developed world and an even higher percentage in the developing countries.
 
# # #
 
About Zealand Pharma
 
Zealand Pharma is a biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs. Zealand is one of the leaders within the peptide area, a growing market with significant drug development activities including treatment of metabolic and cardiovascular diseases. All of Zealand’s products target diseases and symptoms of significant unmet clinical need and commercial potential.
Since 1999, Zealand’s scientists have built a pipeline that includes five compounds in clinical development, two of which have been out licensed to major pharmaceutical companies (Wyeth and Sanofi-Aventis). All Zealand’s compounds emerge from Zealand’s own drug discovery.
 
·          AVE0010/ZP10, a pharmaceutical agent for the treatment of Type 2 Diabetes, has been out-licensed to Sanofi-Aventis (www.sanofi-aventis.com), which is the worlds third largest pharmaceutical corporation with a strong diabetes franchise.
·          ZP120 is an ORL-1 receptor agonist. Zealand has all the rights to the drug, which is currently in Phase II clinical development.
·          GAP-134/ZP1609; a gap junction modifier that prevents both ventricular and atrial arrhythmias in animal models. With its oral formulation, the molecule represents a novel paradigm for the potential chronic prevention of cardiac arrhythmias. US based pharmaceutical giant Wyeth Pharmaceutical is currently conducting Phase I trials in the US.
·          ZP1846 is an innovative treatment for prevention of chemotherapy-induced diarrhea, which may prevent discontinuation and dose modification during cancer chemotherapy. Zealand has all the rights to the drug, and the Company is currently conducting clinical Phase I trials in the US.
·          ZP1848 is a novel paradigm for the treatment of Inflammatory Bowel Diseases (e.g. Crohn’s Disease). The compound is in late preclinical development.
 
In addition, Zealand has a rich and broad portfolio of pre-clinical projects targeting a variety of disease areas, including osteoporosis and obesity-related diabetes.
 
Zealand Pharma is based in Copenhagen and has approximately 65 employees.
 
The Company’s investors include BankInvest Biomedical Venture, LD Pensions, Dansk Erhvervsinvestering and Sunstone Capital as well as the leading international biotech investors CDC Innovation and AGF Private Equity (both in Paris) and Life Sciences Partners (Amsterdam).
 
 
 
 
 
 
 



 IT | 2008-01-22
Anevia Announces IPTV Sales Record for 2007

Anevia strengthens its European position - 2007 sales booming
 
Paris - January 22th, 2008 -
 
Anevia, French designer of the FLAMINGO DVB to IP Gateways and the TOUCAN VOD/nPVR servers today announced a 2007 record year, with more than 100 new customers and a 100% growth. Anevia confirms its strong development: turnover has grown 10-fold over the last 3 years only. Anevia technology is used at over 300 IPTV commercial deployments throughout 50 countries.
 
This outstanding performance comes from Anevia's 2 main flagships product ranges: the FLAMINGO DVB to IP family of gateways for live channel streaming over IP, and the TOUCAN family of servers of On-Demand application such as VoD, nPVR, Pause TV, Catch Up TV or Start Over TV.
 
New customers include Telecom Italia France, The BBC, Tele2 of Sweden, Sierre Energie of Switzerland or City Inn in the UK. 2008 is even more promising with many exciting new projects.
 
“From inception in 2003, Anevia has become a reference in the IPTV and VOD arenas in just 4 years. 2007 has been exceptional, exceeding our expectations and improving customer satisfaction at the same time.” added Patrick Rabu, Anevia Sales Director.
 
Benefits from Anevia' value proposition are strong : reduced deployment time, interoperability with major IPTV equipment providers –CAS/DRM, Middleware, Set Top Boxes-, feature richness, ease to use, disruptive innovating software approach versus legacy electronic-based solutions.
 
2008 will see some new milestones such as the opening of new sales and support offices as well as new product launch and major feature releases.
 
 
About Anevia :
 
Anevia is a telecom equipment vendor, specialising on the video element of Triple Play – Video on Demand, Television over IP, network PVR. Unlike traditional electronic solutions, the originality of Anevia's approach is in having opted for an innovative software solution in its devices, which combine broadband and television. Broadcast meets broadband. Technological disruption lies in the development of powerful algorithms for video processing. As a result, Anevia has been able to develop VOD servers and DVB to IP gateways that are more compact, cheaper and quicker to deploy. Created in 2003 by members of VideoLAN VLC mediaplayer team, Anevia is a French firm whose main investor is CDC Entreprises Innovation. Anevia’s products have been deployed by worldwide telecom, xDSL and FTTH providers, broadcasters and system integrators.



 IT | 2008-01-17
Nemoptic renforce son équipe de direction et nomme Philippe Méchanick Directeur Financier

Cette arrivée d'un spécialiste financier expérimenté dans les secteurs de la haute technologie et de la banque renforce Nemoptic désormais arrivée au stade industriel dans la production d'écrans e-paper
 
Magny les Hameaux, France, le 17 janvier 2008 - Nemoptic, société spécialisée dans le e-paper (papier électronique) pour applications portables grand public et professionnelles, annonce aujourd'hui la nomination de Philippe Méchanick au poste de Directeur Financier.
 
Philippe Méchanick, 49 ans, est responsable de l'organisation financière de Nemoptic, start-up française devenue désormais une société industrielle internationale en pleine croissance et disposant de capacités de production. Il s'occupera en priorité d'améliorer l'avantage concurrentiel des écrans e-paper de Nemoptic en termes de coût et d'optimiser la gestion financière internationale de la production et des ventes en Asie, ainsi que des ventes en Amérique du Nord et en Europe. Ces deux points sont essentiels pour structurer la société avant d'aborder la prochaine phase de son développement.
 
« Le recrutement de Philippe Méchanick coïncide avec un moment important de la vie de la société et ses compétences managériales seront un réel atout, alors que nous entamons l'étape suivante de notre développement », précise Jacques Noels, le PDG de Nemoptic. « La production de nos écrans e-paper BiNem est en plein essor et l'arrivée de Philippe nous permet d'assurer la mise en place des structures et des ressources financières nécessaires pour soutenir notre développement à l'international. »
 
Avant de